CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Tivozanib (1mg) +1 moredrug
Likely dose
Tivozanib (1mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01835223
NCT01835223Phase 2Completed
CompareCT.gov

Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma

Roswell Park Cancer Institute·interventional·Posted Apr 18, 2013·Updated Oct 28, 2020

In Brief

A Phase 2 clinical trial evaluating Tivozanib (1mg) and Tivozanib (1.5mg) for Advanced Adult Hepatocellular Carcinoma and Non-Resectable Hepatocellular Carcinoma. Completed, enrolled 33 participants across 2 sites.

Detailed Summary

This phase I/II trial studies the side effects and best dose of tivozanib and to see how well it works in treating patients with liver cancer that has spread to other parts of the body or cannot be removed by surgery. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Adult Hepatocellular Carcinoma, Non-Resectable Hepatocellular Carcinoma
CountriesUnited States
CollaboratorsNational Comprehensive Cancer Network, AVEO Pharmaceuticals, Inc., National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 18, 2013
Enrollment StartJul 11, 2013
Primary CompletionDec 24, 2018
Study CompletionNov 8, 2019
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 13.2 years ago

Interventions

Tivozanib (1mg)drug

Given PO

Tivozanib (1.5mg)drug

Given PO